Last reviewed · How we verify
TAK-861
TAK-861 is a selective, reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
TAK-861 is a selective, reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | TAK-861 |
|---|---|
| Sponsor | Takeda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TAK-861 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism of action is particularly beneficial for patients with type 2 diabetes, as it helps to lower HbA1c levels and improve glycemic control.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy (PHASE3)
- A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions (PHASE2, PHASE3)
- A Study of TAK-861 in People With Narcolepsy Type 1 (PHASE3)
- A Study of TAK-861 for the Treatment of Narcolepsy Type 1 (PHASE3)
- A Study of TAK-861 in Participants With Narcolepsy Type 1 (PHASE2)
- A Study of TAK-861 in Participants With Narcolepsy Type 2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |